RxDoctor Payments Data

Roy Harris, MD

Family Medicine · Rocklin, CANPI 1780692533

Payments from drug & device makers

$18,818in general payments, 2019–2025

Across 986 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$2K
  • GSK$2K
  • Novo Nordisk$1K
  • Boehringer Ingelheim$1K
  • Lilly USA, LLC$1K
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$18,802100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)142$2,955
AstraZeneca(2 entities)79$1,999
GSK107$1,899
Novo Nordisk86$1,295
Boehringer Ingelheim65$1,218
Lilly USA, LLC57$1,082
Pfizer71$997
Amgen(2 entities)50$990
Bayer17$648
Astellas Pharma US Inc23$505
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC22$378
Merck23$361
Takeda Pharmaceuticals U.S.A., Inc.24$320
Merz North America, Inc.5$312
Kowa Pharmaceuticals America, Inc.20$296
Abbott12$242
Amarin Pharma, Inc.12$236
Boston Scientific10$196
Biohaven Pharmaceutical Holding Company Ltd.11$193
Biohaven Pharmaceuticals, Inc.14$188
Exact Sciences9$184
Johnson & Johnson(2 entities)10$162
Phathom Pharmaceuticals, Inc.7$145
Sanofi-aventis U.S. LLC8$135
Neos Therapeutics, LP6$134
Novartis5$110
E.r. Squibb & Sons, L.L.C.7$105
Hologic Sales And Service, LLC5$101
Bausch Health US, LLC7$99
Antares Pharma, Inc.2$87
Alnylam Pharmaceuticals Inc.5$80
Esperion Therapeutics, Inc.4$70
Sanofi Pasteur Inc.3$67
Pacira Therapeutics, Inc.4$66
IBSA Pharma Inc.4$59
Seqirus USA Inc3$58
Qiagen, LLC2$53
Fidia Pharma USA Inc.4$53
Dexcom, Inc.2$52
Eisai Inc.3$52
Daiichi Sankyo Inc.2$51
Cranial Technologies, Inc3$47
Medtronic2$44
Verity Pharmaceuticals Inc.3$44
Collegium Pharmaceutical, Inc.2$37
Bioventus LLC2$37
Arbor Pharmaceuticals, Inc.3$36
Corium, LLC2$34
Revance Therapeutics, Inc.1$33
Idorsia Pharmaceuticals US Inc2$30
Aimmune Therapeutics, Inc.1$29
Ironwood Pharmaceuticals, Inc1$19
Therapeuticsmd, Inc.1$18
Azurity Pharmaceuticals, Inc.1$17
Intra-sana Laboratories1$17
Halozyme Inc1$17
Xeris Pharmaceuticals, Inc.1$17
Currax Pharmaceuticals LLC1$16
AMAG Pharmaceuticals, Inc.1$16
Kaleo, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,818 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$209,732
Medicare patients
402
Services billed
3,742

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide154$205,232
EliquisApixaban101$107,818
MounjaroTirzepatide56$95,826
Cosentyx Sensoready (2 Pens)Secukinumab13$94,181
RybelsusSemaglutide34$85,031
JardianceEmpagliflozin63$80,418
JanuviaSitagliptin Phosphate32$44,341
Breztri AerosphereBudesonide/Glycopyr/Formoterol39$32,000
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$28,583
MyrbetriqMirabegron23$26,320
XareltoRivaroxaban13$21,434
FarxigaDapagliflozin Propanediol20$21,237
LinzessLinaclotide16$15,525
EdarbiAzilsartan Medoxomil17$11,789
TrintellixVortioxetine Hydrobromide21$10,998

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,295$290,263188 claims
PfizerEliquis$997$107,818101 claims
Lilly USA, LLCMounjaro$1,082$95,82656 claims
Boehringer IngelheimJardiance$1,218$80,41863 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$1,999$58,05174 claims
MerckJanuvia$361$44,34132 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,899$37,48449 claims
Astellas Pharma US IncMyrbetriq$505$26,32023 claims
Johnson & JohnsonXarelto$162$21,43413 claims
AbbVieLinzess, Synthroid$2,955$17,50338 claims
Arbor Pharmaceuticals, Inc.Edarbi$36$11,78917 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$320$10,99821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Rocklin

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →